Kenvue is reportedly considering selling or spinning off its skin health and beauty unit following sales slumps and damaging health allegations against its pain reliever, Tylenol. Analysts report that the division, despite declining sales, could be valued at US$6–9 billion. The unit includes brands such as Neutrogena, Aveeno, and Clean & Clear. There is reported interest in Neutrogena and Aveeno.
The History of Hunter Boots
With the weather finally, slowly starting to heat up and April showers nearly upon us – what better time to take you on a guided










